Overview
EYPT market data
Price History
EYPT price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$3.17 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.67 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -10,994.7% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $9.65 – $19.11 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $1.1B · P/B 4.94 · P/S 404.94.
Company News
Paycom Software To Rally Around 32%? Here Are 10 Top Analyst Forecasts For ThursdayBenzinga · Aug 6, 2026, 12:31 PM
Cantor Fitzgerald Maintains Overweight on EyePoint, Raises Price Target to $55Benzinga · Aug 6, 2026, 12:24 PM
HC Wainwright & Co. Maintains Buy on EyePoint, Lowers Price Target to $27Benzinga · Aug 6, 2026, 10:54 AM
EyePoint Pharmaceuticals Q2 EPS $(1.09) Misses $(0.95) Estimate, Sales $507.000K Beat $406.857K EstimateBenzinga · Aug 5, 2026, 11:30 AM
8-K filing — EyePoint, Inc. (EYPT)SEC EDGAR · Aug 5, 2026, 11:05 AM
EyePoint Pharmaceuticals To Pay $4.6M to Resolve False Claims Act AllegationsBenzinga · Jul 17, 2026, 2:22 PM
This Rambus Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For ThursdayBenzinga · Jul 16, 2026, 11:46 AM
Stifel Initiates Coverage On EyePoint with Buy Rating, Announces Price Target of $40Benzinga · Jul 16, 2026, 9:48 AM
Cantor Fitzgerald Assumes EyePoint at Overweight, Announces Price Target of $47Benzinga · Jul 8, 2026, 1:15 PM
Chardan Capital Maintains Buy on EyePoint, Raises Price Target to $65Benzinga · Jul 1, 2026, 1:00 PM